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http://dx.doi.org/10.1016/j.ccr.2012.08.028SUMMARYExpression of microRNAs (miRNAs) is under stringent regulation at both transcriptional and posttranscrip-
tional levels. Disturbance at either level could cause dysregulation ofmiRNAs. Here, we show thatMLL fusion
proteins negatively regulate production of miR-150, an miRNA widely repressed in acute leukemia, by
blocking miR-150 precursors from being processed to mature miRNAs through MYC/LIN28 functional
axis. Forced expression of miR-150 dramatically inhibited leukemic cell growth and delayed MLL-fusion-
mediated leukemogenesis, likely through targeting FLT3 and MYB and thereby interfering with the HOXA9/
MEIS1/FLT3/MYB signaling network, which in turn caused downregulation of MYC/LIN28. Collectively, we
revealed a MLL-fusion/MYC/LIN28xmiR-150xFLT3/MYB/HOXA9/MEIS1 signaling circuit underlying the
pathogenesis of leukemia, where miR-150 functions as a pivotal gatekeeper and its repression is required
for leukemogenesis.INTRODUCTION
MicroRNAs (miRNAs), a class of small, noncoding RNAs, are
important for posttranscriptional gene regulation in both health
and disease (He and Hannon, 2004; Xiao and Rajewsky, 2009).
The stringent control of miRNAs, at both the transcriptional
and posttranscriptional levels, is critical for maintaining a variety
of important biological processes, including development, differ-Significance
Although altered expression of many miRNAs has been repor
tional mechanisms and pathologic functions remain less unde
gulated in most cases of acute myeloid leukemia (AML). In AM
inhibited by theMLL-fusion/MYC/LIN28 functional axis. Further
in MLL-associated leukemogenesis through repressing the ex
subsequently interfering the HOXA9/MEIS1/FLT3/MYB/MYC/
a signaling circuit in leukemogenesis, in which the posttransc
necessary event. Thus, our results may provide optional strate
524 Cancer Cell 22, 524–535, October 16, 2012 ª2012 Elsevier Inc.entiation, and hematopoiesis (Siomi and Siomi, 2010). After
being transcribed by RNA polymerase II, the primary miRNA
transcripts (pri-miRNAs) would be under a two-step bio-
cleavage process. In the cell nucleus, the Microprocessor,
containing an RNaseIII enzyme Drosha and its cofactor
DGCR8, crops the pri-miRNA into a 70 nucleotide (nt) hairpin
structured precursor (pre-miRNA), which is then exported to
the cytoplasm and cleaved by another RNaseIII enzyme, Dicer,ted in various cancers, including leukemia, their dysregula-
rstood. Here, we show that miR-150 is significantly downre-
L with MLL rearrangements, the maturation of miR-150 is
more, miR-150 itself functions as a pivotal tumor suppressor
pression of FLT3 and MYB, two essential oncogenes, and
LIN28 signaling network. Taken together, we report here
riptional repression of miR-150 maturation is a critical and
gies for anti-leukemia therapy.
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miR-150 Is a Pivotal Gatekeeper in MLL Leukemiato remove the ‘‘terminal loop region,’’ or pre-element (preE), and
to yield the mature miRNA (Newman and Hammond, 2010). The
transcriptional regulation of miRNAs has been extensively
studied, but the current understanding of their posttranscrip-
tional control in cancer is limited.
Lin28 is an RNA-binding protein known to block thematuration
of let-7 and is an important modulator in the posttranscriptional
regulation of miRNAmaturation (Heo et al., 2008; Newman et al.,
2008; Viswanathan et al., 2008). Lin28 itself is a direct down-
stream target of Myc (Chang et al., 2009). However, although
MYC is aberrantly overexpressed in various types of cancer
including lymphoma and leukemia (He et al., 2005; Hoffman
et al., 2002; O’Donnell et al., 2005), the involvement of the
MYC/LIN28 axis in the posttranscriptional regulation of miRNA
maturation in hematopoietic malignancies, e.g., acute myeloid
leukemia (AML), is poorly understood.
AML is a heterogeneous group of genetically diverse hemato-
poietic malignancies with variable response to treatment (Chen
et al., 2010). Chromosome translocations are frequently
observed in AML (Rowley, 2008). AML with chromosomal rear-
rangements involving the mixed lineage leukemia gene (MLL) is
associated with a poor prognosis, especially in infants and
individuals with leukemia that arises secondary to previous
chemotherapy (Behm et al., 1996; Krivtsov and Armstrong,
2007; Rowley, 2008). More than 60 different loci that translocate
to theMLL locus have been identified and cloned (Rowley, 2008).
The critical feature of these chromosomal rearrangements is the
generation of a chimeric transcript consisting of 50 MLL and 30
sequences of the partner gene, many of which are involved in
transcriptional regulation. The human AF9 gene at 9p22 is one
of the most common fusion partner genes with MLL (Krivtsov
and Armstrong, 2007).
Several important oncogenes are known to be direct or indi-
rect downstream targets of MLL-fusion proteins. Among those,
homeobox A (HOXA) genes, MEIS1, FLT3, MYB, and MYC are
frequently upregulated inMLL-associated leukemias (Armstrong
et al., 2002, 2003; Schreiner et al., 2001; Zeisig et al., 2004). The
HOXA cluster genes are direct targets of MLL (Milne et al.,
2005a, 2005b; Yu et al., 1995) and MLL fusion proteins promote
their expression by epigenetic mechanisms (e.g., H3K79methyl-
ation) (Bernt et al., 2011; Faber et al., 2009; Krivtsov and Arm-
strong, 2007; Krivtsov et al., 2008). High expression of HOXA9
and its cofactor, MEIS1, was often found in MLL-associated
leukemias (Armstrong et al., 2002; Bullinger et al., 2004; Faber
et al., 2009). FLT3 and its downstream effectors (e.g., AKT,
STAT5, and ERK) are broadly involved in multiple processes of
hematopoiesis and leukemogenesis via regulating the expres-
sion of a group of targets, such as JUN and MYC (Takahashi,
2011). MYC is a transcription factor involved in cell proliferation
and apoptosis and is upregulated in the FLT3-ITD-transduced
CD34+ hematopoietic stem/progenitor cells (Li et al., 2007).
MYB is an essential downstream target of HOXA9/MEIS1
signaling (Hess et al., 2006), and an autoregulatory feedback
loop was reported recently in which MYB binds MLL through
MENIN and regulates expression of HOXA9/MEIS1 directly (Jin
et al., 2010).
AsMYC is aberrantly overexpressed in various types of cancer
including lymphoma and leukemia (He et al., 2005; Hoffman
et al., 2002; O’Donnell et al., 2005), we tested the hypothesisCthat the MYC/LIN28 axis plays an essential role in AML in which
MYC functions as an important downstream target of MLL
fusions and FLT3 through posttranscriptional regulation of matu-
ration of some critical tumor-suppressor miRNAs.
RESULTS
Expression of miR-150 Is Downregulated in Most AML
To identify potential tumor-suppressor miRNAs that are signifi-
cantly downregulated in AML, we performed a bead-based
miRNA expression profiling assay of 52 AML samples (45 patient
samples and seven cell lines; all bearing chromosomal translo-
cations) along with three normal control samples and an Exiqon
miRNA array assay of 100 samples (including 85 AML and 15
normal control samples). In both profiling assays, we found
that miR-150 was the most significantly and consistently down-
regulated miRNA (q < 0.01; significance analysis of microarrays
[SAM]; Tusher et al., 2001) in most of the AML samples, including
those bearing t(8;21), inv(16), t(15;17), andMLL rearrangements,
compared to normal controls (Figure 1).
Downregulation of miR-150 Is Not Related to DNA Copy
Number Changes, Methylation, or Mutations
To understand how miR-150 is downregulated in AML, we first
examined the DNA copy number of the miR-150 locus at
19q13.33 in 33 samples, including 29 AML samples and four
normal controls. As shown in Figure S1A (available online), there
was no significant amplification or deletion of the genomic locus
of miR-150 in MLL-associated or other subtypes of leukemia
samples relative to normal controls. We also assessed the
DNA methylation status of a 475-bp CpG-enriched, immediate
upstream region of the miR-150 gene locus in 19 samples,
including 17 AML samples and two controls, using bisulfate
genomic DNA sequencing methods. No significant changes in
the DNA methylation level of the miR-150 CpG-enriched region
were observed in leukemia samples relative to normal controls
(Figure S1B). Moreover, no mutation was found in either the
precursor miRNA sequence or the CpG island of miR-150.
Together, our data suggest that other mechanism(s) might be
underlying the downregulation of miR-150 in AML.
Expression of miR-150 Is Regulated by MLL Fusion
Proteins at Both the Transcriptional and
Posttranscriptional Levels
In contrast to fusion proteins with transcriptional repressing
functions [e.g., t(8;21), inv(16), t(15;17), etc.] (Chen et al., 2010),
MLL fusion proteins have been shown to act as transcriptional
activators that directly upregulate expression of a group of onco-
genes (e.g.,HOXA genes andMEIS1) andmiRNAs (e.g., miR-17-
92 and miR-196b) (Faber et al., 2009; Li et al., 2012b; Mi et al.,
2010; Popovic et al., 2009; Zeisig et al., 2004). Thus, it is of great
interest to understand how miR-150 expression is downregu-
lated in MLL-associated leukemia.
We first investigated whether forced expression ofMLL fusion
genes can cause downregulation of miR-150. Indeed, we found
that the level of miR-150 was dramatically downregulated by
ectopic expression of MLL-AF9 in normal mouse bone marrow
(BM) progenitor cells (i.e., lineage negative; Lin–) both in vitro
and in vivo (Figure 2A). In HEK293T cells, the level of miR-150ancer Cell 22, 524–535, October 16, 2012 ª2012 Elsevier Inc. 525
Figure 1. Expression of miRNAs that Are Downregulated in Most AML Relative to Normal Controls
(A) miRNAs that are significantly downregulated (q < 0.001; FDR < 0.0001; SAM; Tusher et al., 2001) in AML samples (n = 52) compared to normal bone marrow
(BM) controls (n = 3; one CD15+ myeloid progenitor and two mononuclear [MNC] cell samples) as detected by bead-based method.
(B) miRNAs that are significantly downregulated (q < 0.0001; FDR < 0.0001; SAM) in AML (n = 85) samples than in normal BM controls (n = 15; six CD34+
hematopoietic stem/progenitor, five CD33+ myeloid progenitor, and four MNC cell samples) as detected by Exiqon arrays. Expression data was mean-centered
and the relative value for each sample is represented by a color, with red and green representing a high and low expression, respectively (scale shown in the upper
left). MNC, mononuclear cell; MLL, MLL-associated leukemia.
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miR-150 Is a Pivotal Gatekeeper in MLL Leukemiacorrelated with the overexpression level of MLL-AF9 in a dose-
dependent manner (Figure S1C). Further studies were done
using the MLL-ENL-ERtm cell line, a cell line stably expressing
a conditional MLL-ENL derivative (Zeisig et al., 2004). As shown
in Figure 2B, the level of miR-150 continued to increase after
withdrawal of 4-hydroxytamoxifen (4-OHT) for the indicated
number of days, along with the decreasing level of MLL-ENL.
In order to determine whether the inhibitory effect of MLL
fusions on miR-150 occurs at the transcriptional level, miR-150
primary (i.e., pri-miR-150) and precursor (i.e., pre-miR-150) tran-
scripts weremeasured in theMLL-ENL-ERtm cell line. Strikingly,
the miRNA primary and precursor transcripts decreased to
47%–67% after 4-OHT withdrawal, whereas the level of mature
miR-150 increased 4.8-fold, compared with cells with 4-OHT
treatment (Figure 2C), suggesting that the MLL fusions might
regulate the expression of miR-150 at both the transcriptional
and posttranscriptional levels. Consistently, in the BM cells of
MLL-associated leukemic mice, the levels of both pri-miR-150
and pre-miR-150 were upregulated, whereas the level of mature
miR-150 was decreased (Figure 2D). Similarly, analysis of
leukemic patient samples showed that mature miR-150 was
consistently downregulated, whereas the levels of pri-miR-150
and pre-miR-150 were upregulated in samples withMLL fusions
(Figure S1D).
It was reported that MLL wild-type or MLL fusion proteins
regulate the transcription of a variety of target genes, such as
HOX genes, by directly binding to their promoter region (Milne
et al., 2005a, 2005b; Zeisig et al., 2004, 2003). As shown in Fig-
ure 2E, we determined through chromatin immunoprecipitation526 Cancer Cell 22, 524–535, October 16, 2012 ª2012 Elsevier Inc.(ChIP) assay that MLL fusion proteins bind directly to an imme-
diate upstream region (<1 kb) of the miR-150 locus, and this
binding is associated with increased level of histone H3 lysine
79 di- and tri-methylation (i.e., H3K79me2/3), a marker for active
transcription in MLL-associated leukemic cells (Bernt et al.,
2011; Krivtsov et al., 2008). There is no enrichment of MLL-fusion
binding nor H3K79me2/3 at the control locus that is >10 kb
upstream of the miR-150 locus (Figure 2E). Therefore miR-150
is likely a direct downstream target of MLL fusions.
MLLFusionProteins InhibitmiR-150Maturation through
the MYC/LIN28 Functional Axis
Recently, miR-150 was identified as one of the three miRNAs
other than let-7 that could be repressed by both Lin28 and Myc
(Chang et al., 2009). Interestingly, Myc has been implicated as
a direct target gene of MLL and is frequently upregulated in
MLL-associated leukemia (Schreiner et al., 2001; Zeisig et al.,
2003), whereas Lin28 is a direct target gene of Myc (Chang
et al., 2009). We then sought to investigate whether MYC and
LIN28participate inMLL-fusion-protein-mediated posttranscrip-
tional regulation of miR-150. As shown in Figure 2F, knockdown
ofMLL inMONOMAC-6 cells by siRNA reduced the levels of both
pri-miR-150 and pre-miR-150 to 57% and 40%, respectively,
whereasmaturemiR-150was raised 2-fold, compared to scram-
bled controls. Knockdown of MYC or LIN28 resulted in effects
similar to knockdown of MLL. Overexpression of either MYC or
LIN28efficiently reversed the effects ofMLL knockdownon these
cells (Figure 2F), indicating that MYC and LIN28 might function
as downstream effectors of MLL in regulating the process of
Figure 2. MLL-Fusion Regulates the Level
of miR-150 via the MYC/LIN28 Axis
(A) Relative expression levels of mature miR-150
in MLL-AF9-transduced colony-forming cells
(in vitro) and BM cells of MLL-AF9 leukemic mice
(in vivo; n = 3).
(B) Expression changes of miR-150 and MLL-
ENL during withdrawal of 4-hydroxy-tamoxifen
(4-OHT) (days 0, 4, and 10 are shown) inMLL-ENL-
ERtm cells.
(C) Expression changes of pri-, pre-, and mature
miR-150 transcripts 10 days post 4-OHT with-
drawal in MLL-ENL-ERtm cells.
(D) Expression changes of pri-, pre-, and mature
miR-150 in BM cells of mice with MLL-fusion-
mediated leukemia.
(E) ChIP assays of potential binding of MLL fusion
proteins and MYC to the miR-150 gene locus and
the control locus (i.e., CpG island of FCGRT,
a neighboring gene) in MONOMAC-6 cells.
(F) Expression changes of pri-, pre-, and mature
miR-150 in MONOMAC-6 cells when the expres-
sion of MLL, MYC, and LIN28 was altered.
(G and H) Assessing potential enrichments of pre-
miR-150 and pre-let-7 in the LIN28-protein-RNA
complex in THP-1 andMONOMAC-6 cells by RNA
pull-down assay (G) and RNA-binding protein
immunoprecipitation (RIP) assay (H), coupled with
RT-qPCR. Pre-miR-103 is used as a negative
control. Mean ± SD values are shown. *p < 0.05;
**p < 0.01.
See also Figure S1.
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miR-150 Is a Pivotal Gatekeeper in MLL LeukemiamiR-150 maturation. Notably, forced expression of MYC in
cells with MLL knock-down also significantly upregulated both
pri- and pre-miR-150 transcripts (Figure 2F), implying that MYC
itself may regulate miR-150 primary transcription directly as
well as serving as a downstream effector of MLL fusions. Indeed,
our ChIP assay revealed that MYC also binds directly to the
immediate upstream region of miR-150 (Figure 2E).
Furthermore, Lin28 is likely to target thematuration processing
of precursor miR-150 directly. In MLL-ENL-inducible cell lines,
knockdown of Lin28 resulted in downregulation of pri- and
pre-miR-150, and upregulation of mature miR-150 (Figure S1E),
whereas overexpression of Lin28 in MONOMAC-6 cells pre-
vented the maturation of miR-150 (Figure S1F). To investigate
whether the let-7 pathway is implicated in Lin28-mediated
blockade of miR-150 maturation, we transfected let-7 alone or
together with Lin28 intoMONOMAC6 cells and found that forced
expression of let-7 (40–70-fold increased expression) did notCancer Cell 22, 524–535,result in a significantly increased miR-
150 maturation (Figure S1F), suggesting
that let-7 is not an essential mediator of
this blockade. To determine whether
LIN28 proteins can bind to miR-150
precursor RNA, we performed both RNA
pull-down assay and RNA-binding
protein immunoprecipitation (RIP) assay,
coupled with qPCR. We first used His-
tagged recombinant LIN28 protein to
pull down target RNAs from total RNAisolated from THP-1 cells and the LIN28-RNA complex was puri-
fied with Ni-NTA beads. We found that pre-miR-150 transcripts,
along with let-7 precursor (as a positive control), are significantly
enriched in the LIN28-RNA complex (Figure 2G), suggesting a
potential direct binding between LIN28 and pre-miR-150.
Furthermore, we used an anti-LIN28 antibody to precipitate
endogenous LIN28-RNA complex from MONOMAC-6 cell lyses
via RIP assay, and found that both miR-150 and let-7 precursors
are highly enriched in LIN28 immunoprecipitation complex (Fig-
ure 2H), indicating an association between the miRNA precur-
sors and endogenous LIN28 protein. In contrast, as a negative
control, precursor of miR-103, a miRNA whose maturation was
not influenced by Lin28 (Viswanathan et al., 2008), was not en-
riched in either assay (Figures 2G and 2H).
Taken together, our data suggest that both MLL fusions and
MYC can promote primary transcription of miR-150, whereas
the MYC/LIN28 axis inhibits its posttranscriptional maturation.October 16, 2012 ª2012 Elsevier Inc. 527
Figure 3. miR-150 Inhibits Cell Growth
In Vitro and Leukemogenesis In Vivo
(A) Colony-forming/replating assays of mouse BM
progenitor cells cotransduced with MSCV-PIG+
MSCVneo (Ctrl), MSCV-PIG+MSCVneo-MLL-AF9
(MLL-AF9), or MSCV-PIG-miR-150+MSCVneo-
MLL-AF9 (MLL-AF9+miR-150).
(B) Analyses of viability (VBL) and apoptosis (APT)
of MONOMAC-6 or THP-1 cells 48 hr post-
transfection with MSCV-PIG (Ctrl) or MSCV-PIG-
miR-150 (miR-150).
(C) Effects of miR-150 on the proliferation of
MONOMAC-6 cells.
(D and E) Effects of miR-150 on viability/apoptosis
(D) and proliferation (E) of mouse BM progenitor
cells in the presence or absence of MLL-AF9.
Mean ± SD values are shown. *p < 0.05; **p < 0.01.
(F and G) Effects of miR-150 inMLL-AF9-mediated
leukemogenesis in vivo. Kaplan-Meier curves are
shown for three groups of transplanted mice
including control (n = 10), MLL-AF9 (n = 12), and
MLL-AF9+miR-150 (n = 11) in a primary BMT assay
(F), and for two groups of transplanted mice
including MLL-AF9+miR-150 (n = 12) and MLL-
AF9 (n = 9) in secondary BMT assay (G).
See also Figure S2.
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miR-150 Is a Pivotal Gatekeeper in MLL LeukemiamiR-150 Inhibits Cell Proliferation/Transformation
In Vitro and Leukemogenesis In Vivo
In order to investigate whether miR-150 has an antagonistic
action on the oncogenicity of MLL fusions, we performed
colony-forming/replating assays. Mouse BM progenitor cells
transduced with MSCV-PIG (bearing a PGK-puromycin-IRES-
GFP cassette; He et al., 2005) or MSCV-PIG-miR-150, together
with MSCVneo or MSCVneo-MLL-AF9, were plated on methyl-
cellulose medium. The colonies were replated every 7 days
under the same conditions. As shown in Figure 3A, cotransduc-
tion of miR-150 and MLL-AF9 caused a significant reduction in
colonies compared to transduction ofMLL-AF9 alone, indicating
that forced expression of miR-150 (Figure S2A) strongly inhibits
the colony-forming capacity induced by MLL-AF9.
We then explored the effects of ectopic expression of
miR-150 on human MLL-associated leukemic cells. As shown
in Figure 3B, forced expression of miR-150 (Figure S2B) signifi-
cantly decreased cell viability and increased apoptosis in
MONOMAC-6/t(9;11) and THP-1/t(9;11) cells. Moreover, over-
expression of miR-150 consistently inhibited the proliferation
of MONOMAC-6 cells (Figure 3C). Similarly, in retrovirally trans-
ducedmouse BMprogenitor cells, we found that in the presence
of MLL-AF9, forced expression of miR-150 significantly
decreased cell viability and increased apoptosis (Figure 3D), as
well as inhibited cell growth (Figure 3E).
In order to elucidate the in vivo role of miR-150 in leukemogen-
esis, we performed primary BM transplantation (BMT) assay and
found that forced expression of miR-150 (Figure S2C) signifi-
cantly delayed leukemogenesis mediated by MLL-AF9 (median
overall survival, 110 days versus 56 days; p < 0.001, log-rank
test) (see Figure 3F). We then performed secondary BMT and
showed that miR-150+MLL-AF9 leukemic cells developed528 Cancer Cell 22, 524–535, October 16, 2012 ª2012 Elsevier Inc.AML in secondary recipient mice remarkably slower than MLL-
AF9 leukemic cells (median overall survival, 70 days versus
42 days; p < 0.001; Figure 3G). The miR-150-alone group did
not show visible differences compared to the control group,
either in survival or in the morphology of cells and tissues (data
not shown). These findings suggest that miR-150 does play a
critical tumor suppressor role in preventing MLL-associated
leukemogenesis.
miR-150 Targets Both MYB and FLT3
To identify potential target genes of miR-150 in MLL-associ-
ated leukemia, we performed Agilent custom-design arrays of
the eight human de novo MLL-associated AML and nine
normal control (including three CD34+, two CD33+, and four
MNC) samples that were used in Exiqon miRNA profiling assay
(see Figure 1B). By correlating expression of predicted target
genes and miR-150 across the above 17 samples, we identi-
fied 158 putative target genes that exhibited a significant
inverse correlation of expression with miR-150 (p < 0.05;
Pearson correlation). Analysis of Affymetrix Exon arrays of 15
additional human MLL-associated leukemia samples and nine
normal controls (including three each of CD34+, CD33+, and
MNC) (Li et al., 2012b) revealed that 22 of the above 158
candidate target genes were significantly overexpressed (q <
0.05; false discovery rate [FDR] < 0.01; SAM; Tusher et al.,
2001) in MLL-associated leukemia samples relative to normal
controls. Furthermore, in the analysis of Affymetrix gene arrays
of nine MLL-AF9-mediated mouse leukemia samples and six
control samples (Li et al., 2012b), we observed that four (i.e.,
Flt3, Myb, Hdhd2, and Letmd1) of the above 22 candidate
target genes were significantly overexpressed (q < 0.05;
FDR < 0.01; SAM) in MLL-AF9 mouse leukemia samples
Figure 4. miR-150 Targets Both MYB and FLT3
(A) Effects of overexpression of miR-150 on endogenous expression of MYB and FLT3.
(B) Luciferase reporter and mutagenesis assays. Left panel: effects of miR-150 on luciferase activity of the reporter gene bearing wild-type or mutant 30UTR of
FLT3 in HEK293T cells. Right upper panel: Putative miR-150 target site and mutant in the 30UTR of FLT3. Right lower panel: western blot analysis of FLT3 in
MONOMAC-6 cells that were transfected with MSCV-PIG (Ctrl), MSCV-PIG-miR-150 (miR-150), scrambled siRNA control oligos (siNC), or FLT3 siRNAs
(siFLT3).
(C and D) Effects of depletion of MYB or FLT3 by siRNAs on viability (C) and apoptosis (D) of MONOMAC-6, THP-1, or KOCL-48 cells.
(E) Effects of forced expression of MYB-CDS or FLT3-ITD-CDS alone, or together with miR-150, on viability and apoptosis of MONOMAC-6 cells.
(F) Effect of miR-150 on cell viability and apoptosis of Jurkat, U937 and MONOMAC-6 cells.
(G) Effect of miR-150 on the proliferation of Jurkat and U937 cells.
(H) Effects of knockdown ofMyb or Flt3 onMLL-AF9-induced colony-formation of mouse BM progenitor cells. Mean ± SD values are shown. *p < 0.05; **p < 0.01.
See also Figure S3.
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miR-150 Is a Pivotal Gatekeeper in MLL Leukemiarelative to normal controls. The expression patterns of these
four genes in the above three sample sets are shown in
Figure S3.
As FLT3 andMYB have been shown to be broadly involved in
multiple processes of hematopoiesis and leukemogenesis
(Ramsay et al., 2003; Takahashi, 2011) and be critical oncogenes
inMLL-associated leukemia (Armstrong et al., 2002, 2003; Hess
et al., 2006; Zuber et al., 2011), we focused on these two genes
for further studies. Forced expression of miR-150 reduced the
levels of both MYB and FLT3 to 53%–74% and 40%–65%,
respectively, in MONOMAC-6 and THP-1 cells (Figure 4A).
MYB has been reported to be a direct target gene of miR-150
(Lu et al., 2008; Xiao et al., 2007). Luciferase reporter and muta-Cgenesis assays showed that miR-150 also targeted the 30UTR of
FLT3 directly (Figure 4B).
Knockdown of the expression ofMYB or FLT3 by siRNAs can
mimic the effects ofmiR-150 overexpression such as decreasing
cell viability (Figure 4C) and increasing apoptosis (Figure 4D) in
MONOMAC-6, THP-1, and KOCL-48 cells. Cotransfection of
MYB or FLT3-ITD, a constitutively active mutant of FLT3, with
miR-150 completely reversed the effects of miR-150 on cell
viability and apoptosis (Figure 4E). Overexpression of MYB or
FLT3-ITD alone did not show noticeable effects on cell viability
or apoptosis, likely due to the high expression level of endoge-
nous MYB and FLT3 in MLL-associated leukemic cells (Somer-
vaille et al., 2009) (Figure 4E). In FLT3-expression-negative cellancer Cell 22, 524–535, October 16, 2012 ª2012 Elsevier Inc. 529
Figure 5. miR-150 Inhibits MLL-Fusion-
Mediated Leukemogenesis via Regulat-
ing Flt3
(A) Kaplan-Meier curves are shown for three
groups of transplanted mice (n = 5 for each group)
in a primary BMT assay.
(B) Kaplan-Meier curves are shown for two groups
of transplanted mice including MLL-AF9 (n = 9)
and MLL-AF9+shFlt3 (n = 8) in an additional
primary BMT assay.
(C and D) Wright-Giemsa staining of mouse
peripheral blood (PB) and BM, or hematoxylin and
eosin (H&E) staining of mouse spleen and liver.
(E and F) Flow cytometry analyses of mouse BM
cells. The ‘‘blast’’ population was gated by FSC/
SSC (in a red frame; upper panel) and then the
proportions of Gr1+ and/or Mac1+ cells were
analyzed (lower panel).
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miR-150 Is a Pivotal Gatekeeper in MLL Leukemialines (e.g., Jurkat and U937) (Shankar et al., 2007; Yao et al.,
2003), overexpression of miR-150 (Figure S2B) showed
slight, if any, inhibitory effects on cell viability, apoptosis, or
proliferation (see Figures 4F and 4G). Results of colony-form-
ing/replating assays showed that cotransduction of Myb or Flt3
shRNA and MLL-AF9 caused a significant reduction in colonies
compared to transduction of MLL-AF9 alone (Figure 4H),
mimicking the inhibitory effect of miR-150 on colony formation
(see Figure 3A). These results indicate that both Myb and Flt3530 Cancer Cell 22, 524–535, October 16, 2012 ª2012 Elsevier Inc.function as direct targets of miR-150 in
regulating leukemic cell self-renewal.
Repression of Flt3 Activity Is
Required for the Inhibitory Effect
of miR-150 in MLL-Associated
Leukemogenesis
The requirement of Myb function in
MLL-associated cell transformation and
leukemogenesis has been well docu-
mented (Hess et al., 2006; Zuber et al.,
2011), suggesting that the inhibitory
effects of forced expression of miR-150
on leukemogenesis would be, at least in
part, related to its repression of Myb
expression.
To determine whether repression of
Flt3 expression is also required for the
inhibitory effects of miR-150 in MLL-
associated leukemogenesis, we per-
formed a series of in vivo functional
studies. As shown in Figure 5A, the delay
in MLL-AF9-induced leukemogenesis
mediated by forced expression of miR-
150 (Figure S2C) could be largely
reversed by coexpression of FLT3-ITD-
CDS. Our loss-of-function study showed
that knockdown of endogenous Flt3 by
shRNA significantly delayed primary
leukemogenesis mediated by MLL-AF9
(median overall survival, 76 days versus65 days; p < 0.05) (Figure 5B), though not as significantly as
did forced expression of miR-150 (see Figure 3F). Leukemia in
MLL-AF9+miR-150 mice is much less aggressive than that of
the MLL-AF9 group, whereas ectopic expression of FLT3-ITD
remarkably reversed the phenotype caused by miR-150 overex-
pression (Figure 5C). Knockdown of endogenous Flt3 by shRNA
resulted in reduction of leukemic blast cells in both BM
and peripheral blood (PB), similar to that found in miR-150 over-
expressing mice (Figure 5D). There was a decrease in the
Figure 6. A Schematic Model of the MLL-Fusion/MYC/LIN28xmiR-
150xFLT3/MYB/HOXA9/MEIS1 Regulatory Circuit in MLL-Associ-
ated Leukemia
MLL fusion proteins inhibit the maturation of miR-150 through MYC/LIN28,
release miR-150 inhibition on its target genes (FLT3 and MYB), then subse-
quently upregulate expression of MYC, LIN28, HOXA9, and MEIS1. The up-
regulation of MYC/LIN28 further represses the level of mature miR-150 and
enhances/maintains the upregulation of the six genes in this regulatory circuit.
These changes, in turn, result in increased cell proliferation and decreased
apoptosis/ differentiation, and eventually lead to leukemogenesis.
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miR-150 mice, compared to theMLL-AF9 group, whereas coex-
pression with FLT3-ITD significantly increased the Mac-1/Gr-1
double-positive cell ratio (Figure 5E). Knockdown of Flt3 by
Flt3-shRNA (i.e., shFlt3) showed an effect similar to forced
expression of miR-150 on reducing the percentage of Mac-1/
Gr-1 double-positive cells (Figure 5F). These results demon-
strate that the repression of Flt3 activity by miR-150 is, at least
in part, responsible for the inhibitory effects of forced expression
of miR-150 on leukemogenesis.
The MLL-Fusion/MYC/LIN28xmiR-150xFLT3/MYB/
HOXA9/MEIS1 Regulatory Circuit
HOXA9 and its cofactorMEIS1 are two of the best studied critical
downstream target genes of MLL fusion proteins (Krivtsov et al.,
2008; Milne et al., 2005a; Zeisig et al., 2004). MYB has been
reported to be a direct target of HOXA9/MEIS1 signaling (Hess
et al., 2006), whereas a recent study showed that MYB can
also regulate expression of HOXA9/MEIS1 at the transcriptionClevel (Jin et al., 2010), suggesting there is an autoregulatory
feedback loop between them. Interestingly, FLT3 has been
identified as a direct target gene of MEIS1 (Wang et al., 2005)
as well as an upstream regulator ofMYC (Li et al., 2007; Takaha-
shi, 2011). MYC is also a downstream target of MLL fusion
proteins (Dawson et al., 2011; Schreiner et al., 2001) and an
upstream regulator of Lin28 (Chang et al., 2009). These findings
together with the data we showed above suggest that there
is a critical MLL-fusion/MYC/LIN28xmiR-150x FLT3/MYB/
HOXA9/MEIS1 regulatory circuit in MLL-associated leukemia
(see Figure 6).
In this regulatory circuit, MLL fusion proteins function as the
driver. Indeed, in human leukemia samples bearing MLL rear-
rangements, levels of expression of all downstream genes
including MYC, LIN28, HOXA9, MEIS1, MYB, and FLT3 are
significantly increased (p < 0.05, t test) relative to normal control
samples (see Figure S4A). MLL-AF9 retrovirally transduced into
mouse normal BM progenitor cells significantly induced expres-
sion of all six genes both in vitro (Figure 7A) and in vivo (Fig-
ure 7B), confirming that they are downstream target genes of
MLL fusion proteins. In theMLL-ENL-ERtm cell line, their expres-
sion levels were significantly reduced (p < 0.05, t test) in cells
10 days after withdrawal of 4-OHT (Figure S4B), indicating their
dependence on the presence of MLL fusion proteins.
On the other hand, this circuit also highlights the importance of
the posttranscriptional regulation of the miR-150 maturation
process in MLL-associated leukemogenesis. Cotransduction
of miR-150 with MLL-AF9 reduced the MLL-AF9-mediated
induction of expression of the six genes both in vitro (Figure 7A)
and in vivo (Figure 7B), leading to a significant reduction
(p < 0.05) in colony-formation (Figure 3A) and a delay in leukemo-
genesis (Figures 3F and 3G). Similarly, ectopic expression of
miR-150 in MONOMAC-6 cells also downregulated the expres-
sion of all six genes (see Figure 7C), leading to a significant
decrease in cell viability/proliferation and an increase in
apoptosis (Figures 3B and 3C). These results indicate that
mature miR-150 has an influence on the expression of all six
genes in this regulatory circuit through directly targeting FLT3
and MYB, suggesting that posttranscriptional repression of
miR-150 is an essential and required event in the pathogenesis
of MLL-associated leukemia.
In addition, cotransfected FLT3-ITD could completely reverse
the effects of ectopic expression of miR-150 in MONOMAC-6
cells on the expression of the six genes (Figure 7C) and on cell
viability and apoptosis (see Figure 4E). Notably, forced expres-
sion of FLT3-ITD alone could significantly increase expression
(p < 0.05) of all six genes (Figure 7C). These data indicate that
FLT3 is an essential target gene of miR-150 and a critical compo-
nent of this regulatory circuit.
The Strong and Widely Existing Inhibitory Effect
of miR-150 on Cell Transformation
We have also conducted in vitro colony-forming/replating
assays to investigate the functions of several other miRNAs
(e.g., miR-29a, miR-29b, miR-148a, miR-181a, and miR-181b)
in MLL-fusion-mediated cell transformation because these miR-
NAs are also significantly downregulated in humanMLL-associ-
ated AML compared to normal controls (Figure 1) or other
subtypes of AML (Li et al., 2008). However, none of theseancer Cell 22, 524–535, October 16, 2012 ª2012 Elsevier Inc. 531
Figure 7. The Effects of MLL Fusion Proteins, miR-150, and FLT3 on
the Expression of the Six MLL-Fusion Downstream Genes
(A) Effects of miR-150 on expression of endogenous Flt3,Myb, Hoxa9,Meis1,
Myc, and Lin28 in mouse BM progenitor cells in the presence or absence of
MLL-AF9. RNAs were collected from the first passage of colony-forming cells.
(B) Effects ofmiR-150 on the expression of above six genes inmouseMLL-AF9
leukemic BM cells (n = 5 for each group).
(C) Effects of miR-150 and/or FLT3-ITD on expression of the six genes in
MONOMAC-6 cells. Mean ± SD values are shown. *p < 0.05, t test.
See also Figure S4.
Figure 8. The Strong andWidely Existing Inhibitory Effect ofmiR-150
on Cell Transformation
(A) Comparison of inhibitory effect of miR-150 with that of miR-29a, miR-29b,
miR-148a, miR-181a, or miR-181b on MLL-AF9-induced colony forming
capacity of mouse BM progenitor cells.
(B) Relative expression level (upper panel) of ectopically expressed miR-150 in
mouse BM progenitor cells transduced with common leukemic fusion genes
such as MLL-AF9, MLL-ENL, PML-RARA, and AML1-ETO9a/AE9a, and its
effects (lower panel) on the colony-forming/replating capacity of the trans-
duced cells. Mean ± SD values are shown. *p < 0.05; **p < 0.01.
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consistent as miR-150 in inhibiting the cell transformation
(Figure 8A).
In addition, as miR-150 was significantly downregulated in
almost all subtypes of AML (Figure 1), in order to test the role
of miR-150 in other subtypes of AML, we performed colony-
forming/replating assays and found that forced expression of
miR-150 could significantly inhibit both MLL fusion (e.g.,
MLL-AF9 and MLL-ENL) and non-MLL fusion (e.g., PML-RARA
resulting from t(15;17) and AML1-ETO9a/AE9a resulting from
t(8;21))-induced cell transformation (Figure 8B). Thus, miR-150
likely also plays a critical tumor suppressor role in other subtypes
of AML.532 Cancer Cell 22, 524–535, October 16, 2012 ª2012 Elsevier Inc.DISCUSSION
Expression of miRNAs is under stringent regulation at both the
transcriptional and posttranscriptional levels. In the present
study we showed that mature miR-150 level was significantly
downregulated in most AML samples, includingMLL-associated
AML. Strikingly, we found that despite the decreased abundance
of mature transcripts of miR-150, its primary and precursor tran-
script abundance is increased in human MLL-associated AML,
relative to normal controls. We further showed that MLL fusion
proteins could bind to the genomic locus of miR-150 and signif-
icantly promote its primary transcription, leading to increased
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the mature miR-150 abundance was significantly decreased
when MLL fusion genes were expressed, and the opposite is
true whenMLL fusion gene expression was silenced or knocked
down. Thus, an important question arises: What caused such
a discrepancy between primary/precursor and mature miR-150
transcript levels in cells bearing MLL fusion genes?
A recent study showed that Myc binds to the promoter region
of Lin28 and activates its transcription, which is essential
for Myc-mediated let-7 repression (Chang et al., 2009). Interest-
ingly, besides let-7, three additional miRNAs (miR-150, miR-
146a, and miR-210) can also be repressed by both Myc
and Lin28.MYC, awell-known oncogene, is a direct downstream
target gene of MLL fusion proteins and thereby is frequently
upregulated in MLL-associated leukemia (Schreiner et al.,
2001; Zeisig et al., 2003), whereas Lin28 is a direct target gene
of Myc. We therefore investigated whether MYC and LIN28
participate in MLL-fusion-protein-mediated posttranscriptional
repression of miR-150. Indeed, here we showed that thematura-
tion of miR-150 is also regulated byMYC/LIN28, and revealed an
interesting function of MLL fusions in the regulation of miRNA
maturation through activation of the MYC/LIN28 axis.
MiR-150 has been implicated as either an oncogene or a tumor
suppressor in various types of solid tumors (Li et al., 2012a;
Srivastava et al., 2011; Wu et al., 2010; Zhang et al., 2012).
However, its function in the pathogenesis of AML is unknown.
The abundance of miR-150 in different populations of normal
hematopoietic cells, including CD34+ hematopoietic stem/
progenitor cells, CD33+ or CD15+ myeloid cells, and mononu-
clear (MNC) cells, is rather consistent, but such abundance is
significantly downregulated in almost all subtypes of AML
samples, including MLL-associated leukemia, suggesting that
miR-150 might be important in maintaining normal myelopoiesis
and in inhibiting leukemogenesis. Indeed, we showed that
miR-150 plays a significant inhibitory role on MLL-fusion-medi-
ated cell transformation and leukemogenesis, and the inhibitory
effect of miR-150 on cell transformation is much stronger than
other miRNAs.
More importantly, we identified the MLL-fusion/MYC/
LIN28xmiR-150xFLT3/MYB/ HOXA9/MEIS1 regulatory circuit
in MLL-associated leukemia. In this circuit, MLL fusion proteins
function as the driver, and their presence leads to the significant
upregulation of all six downstream genes, MYC, LIN28, FLT3,
MYB, HOXA9, and MEIS1, as well as the primary transcription
of miR-150. The upregulation of MYC/LIN28 results in the
blockade of the miR-150maturation process, which in turn leads
to the release of miR-150 inhibition on FLT3 and MYB expres-
sion. The release of FLT3 and MYB would enhance the expres-
sion of HOXA9, MEIS1, MYC, and LIN28, and further enhance/
maintain the blockade of miR-150 maturation. As a result, the
cells reach and maintain high levels of MYC/LIN28/FLT3/MYB/
HOXA9/MEIS1, and thereby transform the cells and lead to
leukemogenesis.
Our finding that FLT3 is a critical target gene of miR-150 and
an essential component of the regulatory circuit provides further
mechanistic evidence to support the notion that FLT3 is a prom-
ising therapeutic target in the treatment of MLL-associated
leukemia (Armstrong et al., 2003; Stubbs and Armstrong,
2007). On the other hand, miR-150 functions as a pivotal gate-Ckeeper in inhibiting cell transformation and leukemogenesis by
directly targeting FLT3/MYB and thereby inactivating the posi-
tive feedback loops within this circuit. The addition of MLL fusion
proteins disrupts the balance betweenmiR-150 and the other six
genes. As the repression of miR-150 maturation is an essential
event in MLL-fusion-mediated cell transformation and leukemo-
genesis, restoration of mature miR-150 would be an attractive
strategy to treatMLL-associated leukemia alone, or in combina-
tion with other strategies, in the future.
Finally, as miR-150 was significantly downregulated in almost
all subtypes of AML and exhibited a significant inhibitory effect
on cell transformation mediated by various types of leukemic
fusion genes, it would be important in the future to systematically
investigate miR-150’s pathologenic role and critical target
genes/pathways in other subtypes of AML, and to reveal the
relevant molecular mechanisms underlying its downregulation.
It would also be important to determine whether the MYC/
LIN28xmiR-150xFLT3/MYB/HOXA9/MEIS1 regulatory circuit
also exists in other subtypes of AML as a whole or at least in
part. Indeed, given the pivotal oncogenic functions of the
MYC/LIN28 axis in various types of cancer including AML
(Chang et al., 2009; He et al., 2005; Hoffman et al., 2002; O’Don-
nell et al., 2005; Viswanathan et al., 2008), it is highly likely that
miR-150, as an essential downstream target and antagonist of
MYC/LIN28, plays a critical tumor-suppressor role in not only
MLL-rearranged AML but also other subtypes of AML and
even in other types of cancer.
Taken together, we revealed a regulatory circuit, namely
MLL-fusion/MYC/LIN28xmiR-150xFLT3/MYB/HOXA9/MEIS1
in MLL-associated leukemia (Figure 6). Our findings may
advance our understanding of the complex molecular mecha-
nisms underlying the development and maintenance of MLL-
associated leukemia, and may also provide effective strategies
to treat MLL-associated leukemia, a disease that is presently
treatment-resistant, and probably also other subtypes of AML,
or even other types of cancer that also utilize at least part of
the signaling circuit we have described herein.
EXPERIMENTAL PROCEDURES
Leukemic Samples and Treatment Protocols
All of the AML patient samples were obtained at the time of diagnosis or
relapse and with informed consent at the University of Chicago Hospital
(UCH), and were approved by the institutional review board of the hospital.
All patients were treated according to the protocols of the hospital.
miRNA and mRNA Expression Profiling Assays
The miRNA expression profiling assays of the 55 human (52 AML and 3
normal control) sample set and the 100 human (85 AML and 15 normal
control) samples were conducted by use of a bead-based method (Li et al.,
2008) and Exiqon miRCURY LNA arrays (v10.0; covering 757 human miRNAs;
Exiqon, Woburn, MA), respectively. The mRNA microarrays of the eight
MLL-associated AML and nine normal control sample set, the 15 MLL-
rearranged AML and nine normal control sample set, and the 15 mouse
sample set were conducted by use of Agilent’s custom-design microarrays
(Agilent Technologies, Santa Clara, CA), Affymetrix GeneChip Human Exon
1.0 ST arrays, and Affymetrix GeneChip Mouse Gene 1.0 ST arrays,
respectively.
Cell Culture and Transfection
THP-1, KOCL-48, U937, and MONOMAC-6 cells were grown in RPMI medium
1640 and transfected using the Amaxa Nucleofector Technology (Amaxaancer Cell 22, 524–535, October 16, 2012 ª2012 Elsevier Inc. 533
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miR-150 Is a Pivotal Gatekeeper in MLL LeukemiaBiosystems, Berlin, Germany). See Supplemental Experimental Procedures
for more details.
Cell Apoptosis and Viability Assay
Cell apoptosis and viability were assessed 48 hr posttransfection using Apo-
Live-Glo Multiplex Assay Kit (Promega, Madison, WI) following the manufac-
turer’s manuals.
Luciferase Reporter and Mutagenesis Assays
Luciferase reporter and mutagenesis assays were conducted as described
previously (Li et al., 2012b), with somemodifications (see Supplemental Exper-
imental Procedures).
Chromatin Immunoprecipitation
Chromatin Immunoprecipitation (ChIP) assay was performed with SABio-
sciences Corporation’s ChampionChiP One-Day kit (QIAGEN, Frederick,
MD) following the manufacturer’s protocol with some modifications (see
Supplemental Experimental Procedures).
Colony-Forming/Replating Assays
These experiments were conducted as described previously (Li et al., 2008)
with some modifications (see Supplemental Experimental Procedures).
Primary and Secondary BMT
All experiments on mice were approved by the Institutional Animal Care and
UseCommittee (IACUC) of the University of Chicago. For primary BMT assays,
normal BM cells of B6.SJL (CD45.1) mice were retrovirally transduced with
corresponding constructs, through two rounds of spinoculation (Li et al.,
2012b), and then injected by tail vein into lethally irradiated (960 rads) 8- to
10-week-old C57BL/6 (CD45.2) recipient mice with 3 3 105 donor cells per
mouse plus a radioprotective dose of 1 3 106 whole BM cells. For secondary
BMT assays, leukemic BM cells isolated from primary recipient mice were
further transplanted into lethally irradiated C57BL/6 secondary recipient
mice with the same dosage as primary BMT.
Flow Cytometry
Cells from PB, BM, spleen, or liver were harvested for analysis of immuno-
phenotypes. After washing with phosphate-buffered saline (PBS) and
blocking unspecific binding with Affinity Purified anti-mouse CD16/32
(eBioscience, SanDiego, CA), cells were stained at 4Cwith various antibodies
diluted in Flow Cytometry Staining Buffer (eBioscience) for 30 min. Sub-
sequently, cells were washed with PBS and resuspended in IC Fixation Buffer
for flow cytometric analysis. APC-conjugated anti-mouse CD11b (Mac-1) and
PE-conjugated anti-mouse Ly-6G (Gr-1) antibodies (eBioscience) were used
for the analyses.
Histopathology and Immunohistochemistry
Tissue samples were fixed in formalin, embedded in paraffin, sectioned and
stained with hematoxylin and eosin (H&E). Cytospins of PB and BM were
stained with Wright-Giemsa.
In Vitro RNA Pull-Down and RIP Assays
THP-1 and MONOMAC-6 cells were used for the RNA pull-down and RIP
assays, respectively, to investigate whether Lin28 protein binds directly to
precursor miR-150 (see Supplemental Experimental Procedures).
ACCESSION NUMBERS
The microarray data have been deposited in the Gene Expression Omnibus
(GEO) repository with the accession numbers GSE30258, GSE34184, and
GSE34185.
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